This website is for Israeli Healthcare Professionals only


Product Information

Botox (Onabotulinum toxin A) is indicated for symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications1.

10 years of experience with Botox for chronic migraine worldwide, demonstrated consistent efficacy, safety, and tolerability2-12.

Botox treatment for chronic migraine is performed according to the PREEMT injection protocol, which has been proven to be effective and safe in reducing the number of headache days, the number of migraine days and improving patient’s quality of life13.

Botox treatment includes 31-39 (at a total dose of 155-195 units) shallow injections into 7 muscle groups in the head and neck areas that may be associated with migraine. Small, fine needles are used, and the injections occur in shallow muscles, beneath the skin13.

Botox treatment takes about 15 minutes14 and should be repeated every 12 weeks.

Botox treatment for chronic migraine is performed by trained neurologists and is included in the complementary insurance of Clalit, Maccabi and Leumit sick funds. 

The image is for illustrative purposes only

Injection Guides


Chronic Migraine -Injection Workbook

Guidance for identifying Botox candidates, the injection procedure, and discussing treatment with patients.

To view the workbook click here

An image is for illustrative purposed only. The treatment should be adjusted to patient anatomy.

Botox for Chronic Migraine – PREEMT Protocol

Based on a publication by Blumenfeld et al 2017 (INSIGHTS into the functional anatomy behind the PREEMPT injection paradigm)

To view PREEMT protocol click here


1. BOTOX® PI 2. Khalil M, et al. J Headache Pain. 2014;15:54. 3. Lee MJ, et al. J Neurol Sci. 2016;363:51–54. 4. Negro A, et al. Springerplus. 2015;4:826. 5. Negro A, et al. J Headache Pain. 2016;17:1. 6. Lia C, et al. Neurol Sci. 2014;35(Suppl 1):175–176. 7. Kollewe K, et al. J Neural Transm. 2016;123(5):533–540. 8. Cernuda-Morollon E, et al. Pain. 2015;156(5):820–824. 9. Aicua-Rapun I, et al. J Headache Pain. 2016;17:112. 10. Demiryurek BE, et al. Neurol Sci. 2016;37:1779–1784. 11. Vikelis M, et al. J Headache Pain. 2016;17(1):84. 12. Santoro A, et al. Neurol Sci 41, 1809–1820 (2020) 13. Blumenfeld A, et al. Headache. 2010;50(9):1406–1418. 14. Data on file, Allergan, 2017; InCrowd Physician Survey

IL-BTX-230012 | Mar 2024